Spineway (ALSPW) Trading Update summary

Revenue performance

• Achieved €11.9 million in 2024 revenue, marking 14% organic growth over 2023.

• H1 revenue rose 20% to €6.5 million; H2 revenue increased 6% to €5.4 million.

• Growth driven by successful integration of Distimp and Spine Innovations acquisitions.

Regional highlights

• Latin America revenue surged 35% to €3.1 million; Asia grew 12% to €1.9 million.

• Europe posted 2.5% growth to €5.3 million, despite delayed product launches and tough market conditions.

Strategic and operational updates

• Premium and innovative product introductions fueled distributor sales in key regions.

• Cost-cutting measures and revenue growth expected to improve operating performance (EBITDA and operating income).

• Reaffirmed ambition to become a major player in less invasive spine treatments.